Health News
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
About FDA approves Infilbray
Last updated:
By FDA | U.S. Food and Drug Administration
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
Source: FDA — Press Releases (official press release). Read the original notice.
Related: Congress Weighs ‘Lifeline for First Responders Act’ to Support Emergency Personnel Nationwide
Related: PREVENT ESRD Act Introduced in U.S. House to Combat Kidney Disease
Related: More States Expand PTSD Treatment for First Responders
Related: Patients First Act of 2026 Introduced in U.S. House of Representatives
See a typo? Report it here.


